GI 197111
Latest Information Update: 10 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class
- Mechanism of Action Cholestenone 5 alpha-reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alopecia
Most Recent Events
- 30 Nov 2000 No-Development-Reported for Alopecia in United Kingdom (Unknown route)
- 13 Aug 1997 Preclinical development for Alopecia in United Kingdom (Unknown route)
- 21 Jul 1997 New profile